Tailored Approach to Non-adherence Advised in Psychotic Patients


Treatment adherence therapy for patients with psychotic disorders should take into account the reasons for each individual's non-adherence.

Treatment adherence therapy (TAT) for patients with psychotic disorders should take into account the reasons for each individual's non-adherence, say researchers who have shown such a strategy to be beneficial.

Study author Anton Staring (Erasmus MC University Medical Center, Tilburg, The Netherlands) and colleagues say the findings are particularly important given that individuals who stop using antipsychotic medication have a three- to five-fold increased risk for relapse and a nearly four-fold increased risk for suicide compared with their adherent peers.

Previous studies of TAT, which incorporates aspects of cognitive-behavioral therapy, have shown mixed findings as to its benefit.

Noting this discordance, recent UK guidelines from the National Institute for Health and Clinical Excellence (NICE) recommend that adherence interventions should not be used in people with schizophrenia.

However, Staring et al speculate that "adherence interventions may be more effective when they take the large variations in reasons for non-adherence into account."

In the current study, the researchers performed a randomized controlled trial of TAT versus treatment as usual (TAU) in 109 outpatients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder.

The researchers first analyzed determinants of non-adherence, dividing them into three "clusters": (1) denial or concealment of illness and failure to integrate treatment into daily life; (2) dissatisfaction with medication because of its side effects or low efficacy; and (3) deficiency in cognitive skills or lack of daily structure to participate effectively in the treatment.

Reviewing these determinants of non-adherence in patients, the therapists then chose from three treatment modules available: motivational interviewing, medication optimization, and behavioral training.

Staring and team report that patients in the TAT group showed a significantly increased service engagement and medication adherence compared with patients in the TAU group at the end of the 6-month treatment period, with Cohen's d effect sizes of 0.48 and 0.41, respectively - which represent "clinical significance," the researchers say.

Six months after completion of the intervention TAT patients still showed significantly greater service engagement and medication adherence compared with TAU patients, although the effect sizes had reduced somewhat, at 0.39 and 0.30, respectively.

Notably, in the total study period one (1.9%) patient in the TAT group was admitted involuntarily to hospital compared with nine (11.8%) in the TAU group - a borderline significant finding.

"The primary focus of TAT is not on psychoeducation: instead, because it stimulates the person to develop an individual narrative into which treatment can somehow be integrated, individual motives for engagement or adherence may sometimes turn out to be different from what clinicians would find appropriate," Staring et alcomment in the British Journal of Psychiatry.

Source: MedWire

What individualized approaches to adherence do you take in your practice with patients who have psychotic disorders? Have you found that over-arching approaches are ineffective? Tell us what your experiences have been.

More around the Web on Adherence in Psychiatric Patients

  • Are Most of Your Schizophrenic Patients Non-adherent to Treatment?
  • Medication Adherence — Center for Connected Health
  • Order Adherence to Mental Health Treatment from Barnes & Noble
  • Why do Persons with Bipolar Disorder Stop their Medication?
Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Depression Screening: Challenges and Solutions at the Primary Care Level
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
© 2024 MJH Life Sciences

All rights reserved.